|
October 13, 2003
|
Affinergy's Scientific Co-Founder Selected to Speak at BioInterface 2003
Advanced coatings technologies of Affinergy to be presented to group of leading scientific peers and prospective commercial partners.
RESEARCH TRIANGLE PARK, N.C., October 13, 2003 - Affinergy, Inc., a biomaterial coatings company with unique capabilities to regulate biological processes on the surface of synthetic materials, announced today that Dr. Mark W. Grinstaff was selected to present materials at a conference of surface modification experts. The presentation is scheduled as part of the BioInterface 2003 Conference, which is sponsored by the Surfaces in Biomaterials Foundation (www.surfaces.org).
Dr. Grinstaff's presentation is entitled "Designing Functional Coatings for Metals and Plastics Using Combinatorial Phage Display Technology." The unique and proprietary technology was developed in collaboration with Dr. Dan Kenan, Elisabeth B. Walsh, Xin Huang, and James A. Parise at Duke University Medical Center. Dr. Kenan is a scientific co-founder of Affinergy.
"Our scientific team is delighted to have been selected to present at this prestigious gathering of leaders in the surface modification area," said Dr. Grinstaff. "A tremendous amount of scientific research has been invested into developing these interfacial biomaterials. The scientific team is excited that this breakthrough technology is now moving into commercial applications."
"The team of scientists that has been developing this technology for several years is extremely talented," said Peyton Anderson, CEO of Affinergy. "The proven ability to selectively attach and/or repel biologics, cells, proteins, or enzymes to a wide variety of synthetic materials has significant commercial applications. Affinergy is excited to accelerate moving the technology from the laboratory to actual products because it can have a major impact on the quality of healthcare and accelerate further scientific discoveries".
About Affinergy
Affinergy, Inc. develops biomaterial coatings that can selectively bond or repel specific biologics as well as regulate biological reactions at the surface of objects implanted into the body. This proprietary and patented technology for surface modification and biomolecule immobilization is called "Interfacial Biomaterials" (IFBM). Applications include: improving bone ingrowth on orthopedic devices such as hip implants, repelling infections from catheter/medical devices, upgrading the capabilities of blood filters, and "kick-starting" biological processes to grow new arteries. Affinergy is based in Research Triangle Park, NC.
The Surfaces in Biomaterials Foundation
The Surfaces in Biomaterials Foundation is dedicated to exploring creative solutions to technical challenges at the BioInterface by fostering education and multidisciplinary cooperation among industrial, academic, clinical, and regulatory communities. The Surfaces in Biomaterials Foundation provides a forum for the presentation of contributions to surface science. The Foundation's Academic and Supporting Members explore surface characterization and problem-solving techniques important in the manufacturing, development, and research of biomaterials and offer a strong, united voice within the community.
For more information, visit www.affinergy.com or contact Jonathan Gindes at (919) 345-4732.
|
